ArticleNeurology(R) neuroimmunology & neuroinflammation2019
Vitamin D enhances responses to interferon-β in MS.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Single-cell analysis of skin and blood reveals systemic immune responses to ultraviolet B and their impairment in MS.Journal of neuroinflammation · 2026Trial
- Vitamins DFrontiers in immunology · 2022Trial
- Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS.Annals of clinical and translational neurology · 2020Trial
- Article
- Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression.PloS one · 2025Article
- Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Neurology and therapy · 2024Review
- Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.Acta neurologica Belgica · 2024Article
- FTY720 requires vitamin BCell reports · 2023Article
- T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- High-dose vitamin DEClinicalMedicine · 2023Article
- Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis.Frontiers in immunology · 2023Article
- Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles.Frontiers in neurology · 2023Article
- The Role of Nutritional Lifestyle and Physical Activity in Multiple Sclerosis Pathogenesis and Management: A Narrative Review.Nutrients · 2021Review
- Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits.Expert review of anti-infective therapy · 2021Review
- Review
- Putative Role of Vitamin D for COVID-19 Vaccination.International journal of molecular sciences · 2021Review
- Vitamin D and SARS-CoV-2 infection-evolution of evidence supporting clinical practice and policy development : A position statement from the Covit-D Consortium.Irish journal of medical science · 2021Article
- Gene expression profiles of YAP1, TAZ, CRB3, and VDR in familial and sporadic multiple sclerosis among an Iranian population.Scientific reports · 2021Article
- The Roles of Orphan G Protein-Coupled Receptors in Autoimmune Diseases.Clinical reviews in allergy & immunology · 2021Review
- Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the effect of vitamin D3 on interferon-β (IFN-β) response and immune regulation in MS mononuclear cells (MNCs).
methodsMNCs from 126 subjects, including therapy-naive patients with different forms of MS, plus patients with MS receiving IFN-β or glatiramer treatment, plus healthy controls were incubated in vitro with IFN-β-1b ± vitamin D3 (calcitriol). Activation of the IFN-β-induced transcription factor, p-Y-STAT1, and antiviral myxovirus A (MxA) protein was measured with flow cytometry and Western blots; serum proteins were measured with a customized 31-protein multiplex assay.
resultsVitamin D enhanced in vitro IFN responses, as measured by induction of p-Y-STAT1 and MxA in MNCs, T cells, and monocytes. Vitamin D augmentation of IFN responses was seen in untreated and in IFN-β-1b-treated MS. The combination of vitamin D plus IFN-β reduced Th1 and Th17 cytokines, and increased Th2 responses, reversing the effect of IFN-β alone. Exacerbations and progression in untreated patients reduced the vitamin D enhancement of IFN responses. Vitamin D had less effect on IFN response in clinically stable glatiramer-treated than in IFN-β-treated patients.
conclusionVitamin D enhances IFN-β induction of multiple proteins and also reverses the Th1/Th2 bias in MS seen with IFN-β alone. The combination of vitamin D and IFN-β has potential benefit in ameliorating MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.